IMTX Stock Summary and Trading Ideas (Immatics N.V. - | NASDAQ:IMTX)

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Immatics N.V. - trades on the NASDAQ stock market under the symbol IMTX.

As of July 24, 2026, IMTX stock price declined to $9.14 with 171,750 million shares trading.

IMTX has a beta of 1.07, meaning it tends to be more sensitive to market movements. IMTX has a correlation of 0.06 to the broad based SPY ETF.

IMTX has a market cap of $1.23 billion. This is considered a Small Cap stock.

Last quarter Immatics N.V. - reported $9 million in Revenue and -$.50 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.08.

In the last 3 years, IMTX traded as high as $13.77 and as low as $3.30.

The top ETF exchange traded funds that IMTX belongs to (by Net Assets): SPDW, KOMP, CANC, SBIO, ONEQ.

IMTX has outperformed the market in the last year with a return of +41.7%, while the SPY ETF gained +18.2%. However, in the most recent history, IMTX shares have underperformed the stock market with its stock returning -18.0% in the last 3 month period and -8.2% for the last 2 week period, while SPY has returned +5.1% and -1.2%, respectively.

IMTX support price is $8.95 and resistance is $9.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMTX shares will trade within this expected range on the day.